|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Brain Natriuretic Peptide ( BNP ) regulates the production of inflammatory mediators in human THP-I macrophages显示文摘 | Chiurchiu V Izzi V D'Aquilio F | 2008 | Regul Pept2008，148，13： | 1 |
| 2 | Inhibitory action on GHRH-induced GH secretion of chronic treatment breast cancer 显示文摘 | De Marinis L Mancini A Izzi D | 2000 | Clin Endocrinol2000，52，6： | 1 |
| 3 | Brain Natriuretic Peptidc (BNP) regulates the production of inflammatory mediators in human THP- I macrophages 显示文摘 | Chiurchifl V Izzi V D'Aquilio F el al | 2008 | Regul Pept2008，148，13： | 1 |
| 4 | Probiotics: history, definition, requirements and possible therapeutic applications 显示文摘 | Montaho M Araneio F Izzi D | 2002 | Ann hal Med Int2002，17，3： | 1 |
| 5 | Probiotics:history,definition,requirements and possible therapeutic applications显示文摘 | Montalto M Arancio F Izzi D | 2002 | Ann Ital Med Int2002，17，： | 1 |
| 6 | IgA nephropathy : the presence of familial disease does not confer an increased risk for progression 显示文摘 | Izzi C Ravani P Tones D | 2006 | Am J Kidney Dis2006，47，5： | 1 |
| 7 | Boceprevir or telaprevir in hepatitis C virus chronic infection:The Italian real life experience显示文摘AIM: To check the safety and efficacy of boceprevir/telaprevir with peginterferon/ribavirin for hepatitis C virus(HCV) genotype 1 in the real-world settings. METHODS: This study was a non-randomized, observational, prospective, multicenter. This study involved 47 centers in Italy. A database was prepared for the homogenous collection of the data, was used by all of the centers for data collection, and was updated continuously. All of the patients enrolled in this study were older than 18 years of age and were diagnosed with chronic infection due to HCV genotype 1. The HCV RNA testing was performed using COBAS-Taq Man2.0(Roche, LLQ 25 IU/m L). RESULTS: All consecutively treated patients were included. Forty-seven centers enrolled 834 patients as follows: Male 64%; median age 57(range 18-78), of whom 18.3% were over 65; mean body mass index 25.6(range 16-39); genotype 1b(79.4%); diagnosis of cirrhosis(38.2%); and fibrosis F3/4(71.2%). The following drugs were used: Telaprevir(66.2%) and PEG-IFN-alpha2a(67.6%). Patients were na?ve(24.4%), relapsers(30.5%), partial responders(14.8%) and null responders(30.3%). Overall, adverse events(AEs) occurred in 617 patients(73.9%) during the treatment. Anemia was the most frequent AE(52.9% of cases), especially in cirrhotic. The therapy was stopped for 14.6% of the patients because of adverse events or virological failure(15%). Sustained virological response was achieved in 62.7% of the cases, but was 43.8% in cirrhotic patients over 65 years of age. CONCLUSION: In everyday practice, triple therapy is safe but has moderate efficacy, especially for patients over 65 years of age, with advanced fibrosis, nonresponders to peginterferon + ribavirin. | Antonio Ascione Luigi Elio Adinolfi Pietro Amoroso Angelo Andriulli Orlando Armignacco Tiziana Ascione Sergio Babudieri Giorgio Barbarini Michele Brogna Francesco Cesario Vincenzo Citro Ernesto Claar Raffaele Cozzolongo Giuseppe D’Adamo Emilio D’Amico Pellegrino Dattolo Massimo De Luca Vincenzo De Maria Massimo De Siena Giuseppe De Vita Antonio Di Giacomo Rosanna De Marco Giorgio De Stefano Giulio De Stefano Sebastiano Di Salvo Raffaele Di Sarno Nunzia Farella Laura Felicioni Basilio Fimiani Luca Fontanella Giuseppe Foti Caterina Furlan Francesca Giancotti Giancarlo Giolitto Tiziana Gravina Barbara Guerrera Roberto Gulminetti Angelo Iacobellis Michele Imparato Angelo Iodice Vincenzo Iovinella Antonio Izzi Alfonso Liberti Pietro Leo Gennaro Lettieri Ileana Luppino Aldo Marrone Ettore Mazzoni Vincenzo Messina Roberto Monarca Vincenzo Narciso Lorenzo Nosotti Adriano Maria Pellicelli Alessandro Perrella Guido Piai Antonio Picardi Paola Pierri Grazia Pietromatera Francesco Resta Luca Rinaldi Mario Romano Angelo Rossini Maurizio Russello Grazia Russo Rodolfo Sacco Vincenzo Sangiovanni Antonio Schiano Antonio Sciambra Gaetano Scifo Filomena Simeone Annarita Sullo Pierluigi Tarquini Paolo Tundo Alfredo Vallone | 2016 | World Journal of Hepatology2016，8，22： | 1 |
| 8 | Brain natriuretic peptide (BNP')regulates the production of inflammatory mediators in human THP-1 mac- rophages 显示文摘 | Chiurehiu V Izzi V D'Aquilio F | 2008 | Regul Pept2008，148，13： | 1 |
| 9 | Brain natriuretic peptide(BNP) regulates the production of inflammatory mediators inhuman THP-1 macrophages 显示文摘 | Ghiurchiu V Izzi V D Aquilio F | 2005 | Hegul Pept2005，148，13： | 1 |
| 10 | Brain natriuretic peptide (BNP) regulates the production of inflammatory mediators in human THP-1 macrophages显示文摘 | Chiurehiu V Izzi V D'Aquilio F | 2008 | Regul Pept2008，148，： | 1 |
| 11 | IgA nephropathy:the presence of familial disease does not confer an increased risk for progression显示文摘 | Izzi C Ravani P Tones D | 2006 | Am J Kidney Dis2006，47，5： | 1 |
| 12 | Endomorphin-1 prevents lipid accumulation via CD36 down-regulation and modulates cytokines release from human lipid-laden macrophages显示文摘 | Chiurchiu V Izzi V D'Aguilio F | 2011 | Peptides2011，32，1： | 1 |
| 13 | IgA Nephrothy:The presence of familial disease dose not confer an increased risk for progression显示文摘 | Izzi C Ravani P Torres D | 2006 | Am J Kidney Dis2006，5，： | 1 |
| 14 | Brain natriuretic peptide regulates the production of inflammatory mediators in human THP-1 macrophages显示文摘 | Chiurchii V Izzi V D'Aquilio F | | 0，，13： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员